In December 2013 we successfully acquired HER-Vaxx  from Biolife Science

Immuno-Oncology Industry News

Date Title

Novel Approaches Explored in HER2-Positive Gastric Cancer - Yelena Y. Janjigian, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center


Cancer Immunotherapy: The Cutting Edge Gets Sharper  - Scientific American October 2015


Axel Hoos, GSK interviewed at BIO 2015: Focusing on immuno-oncology and cancer epigenetics


Cancer vaccines field to see sizable growth, report says


GSK takes another big swing at cancer drug R&D - article featuring Dr Axel Hoos, NED at Imugene


The Immune System Fights Back with CART


Yes to Flexus: The Science And Strategy Behind A Huge Biotech Return


Fierce Biotech - Bristol-Myers' pioneering PD-1 drug Opdivo OK'd by FDA for melanoma


Wall Street Journal, Ron Winslow - How the Promise of Immunotherapy is Transforming Oncology


The Australian - Biomedical stocks racing to solve a $40bn problem


Pfizer ($PFE) is determined to be a major player in the fast-emerging field of immuno-oncology, and the pharma giant is paying handsomely to buy its way into an anti-PD-L1 program now underway at Merck KGaA. In a deal announced Monday Pfizer outlined plans to pay a whopping $850 million upfront and up to $2 billion in milestones for the right to co-develop and co-market MSB0010718C and any other IO drugs they put in the pipeline.  Click here to view.


© Imugene 2018. All rights reserved. ABN 99 009 179 551